Session: S31-AR and Coactivators in Prostate Cancer
Room 256 (Moscone Center)
Androgen Receptor constitutively active splice variants (ARsv) in are commonly seen in castrate resistant prostate cancer (CRPC), especially with second generation anti-androgen therapies. However, their impact on tumor progression may vary between tumors or tumor metastases and response to treatments may also be variable. In the presentation the pathways by which the the ARsvs may signal, the mechanisms for selection of pathways, potential impact on tumor progression, and whether these pathways are different from the canonical AR pathways will be discussed.